To Be Discontinued Injection Analgesia/Addiction
Neostigmine Methylsulfate In · 242 days since initial FDA posting
Brand: NEOSTIGMINE METHYLSULFATE
FDA lists Neostigmine Methylsulfate In as To Be Discontinued (Fresenius Kabi USA, LLC).
No availability text on this FDA row.
Neostigmine Methylsulfate Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Neostigmine Methylsulfate Injection
- Manufacturer
- Fresenius Kabi USA, LLC
- Dosage Form
- Injection
- Presentation
- Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)
- Package NDC
- 63323-413-10
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jan 12, 2026
- Last Updated
- Jan 12, 2026
- Therapeutic Category
- Analgesia/Addiction
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.